Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“During the Biden administration, HHS adopted an alternative test for "accepted medical use" that considers "widespread" clinical experience with a drug and requires "some credible scientific support" for at least one application.”
UnverifiableConfidence: LOW

Reasoning

The evidence explicitly says that during the Biden administration, HHS embraced an alternative test for "accepted medical use" that considers "widespread" clinical experience and requires "some credible scientific support" for at least one application, matching the claim.

On confidence: The claim is directly supported by the provided excerpt from a Reason.com article citing a GAO report that states HHS adopted an alternative test during the Biden administration.

Important context

The alternative test is described as differing from the prior DEA criteria and aligns with the claim's description of the test's components.

Evidence

Supporting (2)

  • Tier 1 — Primary source
    Federal drug scheduling relies on vague criteria, GAO report finds

    similar to the evidence that the Food and Drug Administration (FDA) demands to approve a drug for prescription use, the DEA's definition essentially equated "accepted medical use" with FDA approval. During the Biden administration, the HHS…

  • Tier 1 — Primary source
    Federal drug scheduling relies on vague criteria, GAO report finds

    cannabis illustrates that puzzle. When Congress enacted the CSA in 1970, it placed marijuana in Schedule I, and the Drug Enforcement Administration (DEA), which had the authority to reclassify drugs in consultation with the Department of…

Limitations

The verification relies solely on the provided excerpt; no additional sources are consulted to confirm the broader context or official policy documents. No independent origin corroborated this claim, so it cannot be verified and confidence cannot be high.

Last verified:
Oct 2, 2026, 4:28 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

Hazy Drug Classification Criteria Invite Dubious Bureaucratic Judgments

Reason · Jacob Sullum